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Abstract: Lovastatin, an anti-cholesterol drug, is a potent inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-CoA  
reductase (HMG CoA reductase) that catalyses conversion of HMG CoA to mevalonate involved in cholesterol  
biosynthesis. Lovastatin does not only find a role as anti-cholesterol agent but also plays a key role as an  
anti-inflammatory agent, cancer cell apoptosis, renal function restoration, treatment for bone disorders etc. Production of 
statins has been undertaken by Submerged Fermentation (SmF) and Solid State Fermentation (SSF) by using fungi. In 
view of the advantages of SSF over SmF, the focus has shifted to production by SSF in recent years. The use of various 
agro based wastes as substrates has been proven. With recent developments in molecular biology and genome studies it 
has been able to decode genetic aspects of lovastatin gene expression levels. This review gives an insight into works  
reported on lovastatin production by SSF, various substrates employed, mutation studies, optimisation parameters,  
molecular studies and medical application of lovastatin.  
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INTRODUCTION 
 The World Health Organisation reported that cardiovas-
cular diseases (CVD) claimed 17.3 million lives in 2008 and 
predicts that an estimated 23.6 million people will die of 
CVD by the year 2030. The lower and middle income coun-
tries constituted 80% of the mortalities [1]. Today, the aver-
age age in which a person may suffer a heart attack has come 
down drastically almost to range between 30-40 years with 
hypercholesterolemia being one of the primal causes. The 
treatment for hypercholesterolemia focuses on decreasing the 
Low Density Lipoprotein (LDL) cholesterol and is best 
achieved by medications when diet and exercise are insuffi-
cient. Fungi produce a wide variety of biologically active 
compounds, a large proportion of which are produced by the 
polyketide biosynthetic pathway. Fungal polyketides com-
prise a very large and structurally very diverse group and 
many display important biological activities such as antibi-
otic and other related pharmacological properties [2]. Among 
the fungal metabolites, statins (anti-cholesterol compounds) 
are considered as the most important class produced by the 
polyketide pathway. Statins comprise of Compactin Lovas-
tatin, Pravastatin, Simvastatin, Rosuvastatin, Atorvastatin 
and Fluvastatin. Compactin and lovastatin are of biological 
origin whereas simvastatin, pravastatin, rosuvcastatin etc are 
chemical modifications of compactin and lovastatin [3]. The 
biosynthetic pathway involved in statin production starts 
from acetate units linked to each other in head to- tail fash-
ion to form polyketide chains. Lovastatin prevents formation 
of mevalonate from HMG Co-A [4, 5] by competitively in- 
hibiting the enzyme HMG CoA Reductase. Lovastatin can 
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exist in two forms i.e hydroxyl from and lactone form, of 
which the hydroxyl-form is the active drug. The lactone 
forms (e.g. lovastatin, simvastatin, cerivastatin) are very 
lipophilic while the acid forms are hydrophilic (e.g. atorvas-
tatin, fluvastatin, pravastatin [6]. The global ruling rate of 
statins is $400-$1200 per kilogram with a growth rate of 
30% per annum (The Economic Times, October 13, 2003.). 
Lovastatin and other natural and synthetic derivatives consti-
tute the statin group that has caught the eye of numerous 
pharmaceutical companies.  
 Lovastatin is obtained from different genera and species 
of filamentous fungi. Several fungal genera including Asper-
gillus, Penicillium, Monascus, Paecilomyces, Trichoderma, 
Scopolariopsis, Doratomyces, Phoma, Phythium, Gymnoas-
cus, Hypomyces and Pleurotus are reported as lovastatin 
producers [3]. In addition even the Basidiomycetes mush-
rooms have recently reported to be used. Pleurotus sp and its 
related strains produce higher concentrations of lovastatin. A 
marine actinomycete has also been reported to produce lo-
vastatin [7]. This review gives an insight into lovastatin pro-
duction by SSF approach in the last 5-6 years and the possi-
ble multiple (pleiotropic effects) applications of lovastatin in 
medical field. 
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History 
 In the 1950’s a US based company, Wm. S. Merrell Co., 
identified a compound with anti-cholesterol property and 
named it as Triparanol (MER/ 29) which blocked the con-
version of desmosterol to cholesterol, the final stage in cho-
lesterol biosynthesis. Later it was reported that triparanol is 
ineffective drug and associated with lens cataracts, hair loss 
in rats and dogs, also higher doses causing blindness in rats. 
This led to ban on triparanol. Masao Kuroda and Akira 
Endo, supported by their team, at Sankyo Co. Tokyo, 
screened numerous fungi and discovered that Penicillium 
citrinum produced what they were seeking for. The metabo-
lite from Penicillium citrinum was christened as ML236B 
(referred to as compactin), an anti-cholesterol agent. With 
several tests the carcinogenic effects of compactin came to 
light as they noted lymphomas in dogs treated with higher 
doses of compactin. This led to company to abruptly halting 
clinical trials. Later, Merck, a competitor had initiated works 
on discovering anti-cholesterol drug and reported the pro-
duction of Mevinolin (Lovastatin) from Aspergillus terreus. 
Later, it was discovered that in fact what they called as lym-
phomas associated with compactin were actually the accu-
mulation of reductase proteins in endoplasmic reticulum in 
response to statin therapy. Merck got the approval from FDA 
in 1987 to release Mevinolin into the market, thus, starting 
the statins era. In 1979, Endo reported that Monascus sp also 
produced reductase inhibitors and obtained a patent for the 
same [8, 9].  
Pleiotropic Effects of Lovastatin 
 The clinical, epidemiological and pathological applica-
tions of lovastatin have been well documented. It finds its 
applications for more medical uses such as reducing in-
stances of peripheral vascular diseases, prevention of 
strokes, stabilization of artheromatous plaques, improved 
endothelial functions and prevention of thrombus formation 
[10, 11]. 
 Alzheimers Disease (AD): AD is associated with forma-
tion of amyloid plaques in brain due to production of neuro-
toxic amyloid ? protein (produced by alternate processing of 
amyloid precursor protein). Animal and cell culture experi-
ments reported decreased prevalence of AD using lovastatin. 
Human trials did not succeed 100% and more work needs to 
be warranted in the same area to attribute exact role of lovas-
tatin [12].  
 Multiple Sclerosis (MS): Lovastatin supressed production 
Tumor Necreosis Factor- ? (TNF-?) by Interferon-? (IFN-?). 
This resulted in decreased level of inflammatory response 
and protecting the host cells by cellular damage. Lovastatin 
also inhibited Major Histocompatibiliy Complex-II (MHC-
II) upregulation in Antigen Presenting Cells (APC’s). 
Atorvastatin prevented or reversed paralysis in murine Expe-
riemental Autoimmune Encephalitis (EAE) models. This 
indicates immune-modulatory role of lovastatin [6]. 
 Bone Disorders: prolonged infusions or large doses of 
lovastatin stimulate bone formation both in-vivo and in-vitro 
as noted in murine models. Pre-clinical studies report that 
nano particle delivery of lovastatin may fasten human bone 
fractures [13]. This beneficial effect may also be used in 
treatment of osteoporosis [4]. 
 Renal Protection: kidney damage associated with glome-
rulonephritis may be retarded by lovastatin treatment. This 
may be due to down regulation of inflammatory cytokines 
and activity of GTPases Ras superfamily. The exact role of 
statins is yet to be elucidated [14]. 
 Cancer: Lovastatin is found to induce apoptotic response 
in human acute myeloid leukemia (AML) cells. Inhibition of 
geranylgeranylation of target proteins is the mechanism of 
lovastatin-induced apoptosis in AML cells. The antiprolif-
erative properties of lovastatin may be used as an effective 
anticancer drug. The mechanism underlying lovastatin-
induced apoptosis of malignant cells remains unclear [15, 
16]. Observations have found large reductions in the risk 
(20–55%) of site-specific cancers (colorectal, breast, pros-
tate, lung, and pancreatic) with the use of statin therapy [16]. 
Inhibition of Ras farsenylation is associated with reduction 
and proliferation of cancer in human glioblastoma cells. Fur-
ther studies need to be carried out to exactly predict if satins 
can be used as anti-cancer drug as some trials have failed to 
reproduce results [4]. 
 Rheumatoid Arthritis (RA): Human trials using lovas-
tatin, may help to decrease problems associated with RA by 
immunomodulation and modified endothelial function [4].  
 A recent study reports the role of statins as an immune-
modulator in treatment of vitiligo and its beneficial part in 
graft transplant is being investigated. With its vibrant appli-
cation statins in future will play a vital role in medical and 
pharmaceutical field [10, 11]. 
Solid Substrate Fermentation for Lovastatin Production  
 Lovastatin production and optimisation of fermentation 
parameters has been of great interest since its discovery. 
Many efforts and trials have been performed to increase the 
titre. Initially, all production processes were carried in Sub-
merged Fermentations (SmF) by varying physico-nutritional 
parameters. The submerged processes have not but yielded 
constant results and higher yield (Table 1) and hence a shift 
Table 1. Lovastatin Production by SmF 
S. No. Microorganism Lovastatin Yield (mg/L) References 
1 Aspergillus terreus 0.40 Szakacs et al., 1998 [32] 
2 Aspergillus terreus 2200 Kumar et al., 2000 [33] 
3 Aspergillus terreus 55  Samiee et al., 2003 [34] 
4 Monascus pilosus 725 Miyake et al., 2006 [35] 
5 Monascus purpureus 0.318 Sayyad et al., 2007 [36] 
6 Monascus purpureus 737 Ahmed et al., 2009 [37] 
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towards to Solid State Fermentation (SSF) was gaining 
popularity for multiple industrially important products such 
as enzymes, pigments, antibiotics etc. SSF has been widely 
employed in industrial productions because of its advantages 
such as better process control, maximum substrate utilisa-
tion, lower chances of contamination, easy downstream 
processing etc. Many bacteria and fungi have been utilised 
for production of industrially important products by SSF 
[17]. 
 Lovastatin production also has been carried by SSF ap-
proaches with promising results. The results were far surpris-
ing that expected with high titre of 1110g/gm dry weight of 
substrate [18, 19], thus portraying immense potentials of SSF 
(Table 2). Numerous data is present regarding lovastatin 
production by SmF and optimisation parameters reported [5, 
20, 21].  
 The production of lovastatin by solid state fermentation 
(SSF) has gained popularity as it involves lower media cost, 
stability of the product, increased yield [4, 22] and increased 
porosity [18]. The higher yield associated with SSF is pri-
marily due to increased mycelial density provided with an 
optimum moisture range between 60%-70% [18]. The sub-
strates used in fermentation include wheat bran, rice bran, 
non-glutinous rice, orange peels, grain husks [19, 22, 23]. Of 
all the substrates used, wheat bran has topped as the best one 
with a yield of 3273.4 μg/g [24] and a yield range of 806 
mg/L to 982.3 mg/L [22]. An increase or decrease in mois-
ture content is reported to affect the oxygen and water bal-
ance [24] and thereby decreasing lovastatin yield. Lovastatin 
yield of 730 μg/g of dry weight substrate i.e wheat bran at a 
moisture level of 65% and temperature of 30 OC has been 
reported using mutated strain of A terreus [18]. Rice bran 
was of good choice specially when supplemented with car-
bon & nitrogen source (as rice is poor in nitrogen source) 
and better compared to rice husk [25]. Low protein content 
may be dealt by addition of peptone in substrate. Rice based 
un-supplemented medium yields 1.703 mg/g lovastatin using 
M. purpureus MTCC 369. Rice supplemented with soya 
bean powder, sucrose and yeast extract inoculated with M 
ruber also resulted in high titre [26].  
 Lactose is a slowly metabolized product compared to 
glucose. Rapid glucose metabolism results in formation of 
alcohol, aids in filamentous growth thus resulting in in-
creased medium viscosity and decreased oxygen diffusion 
therefore affecting yield. Initial glucose supplementation in 
bran helped A terreus in higher product accumulation and 
the presence of organic nitrogen source reportedly sup-
pressed lovastatin yield, but too low concentration affects 
biomass formation too [26]. Inorganic nitrogen sources are 
preferred as they aid in higher titre. Selection of glucose (re-
pressive) along with non-repressive carbon source in combi-
nation yields increased lovastatin titre in M pilosus [11]. Glu-
cose and maltose are the best carbon sources (444 mg/L). 
Glucose is said to exert repressive action but a combination 
of glucose, glycerol and peptone in medium is best for M 
pilosus to produce lovastatin. Dextrose, KH2PO4 and FeSO4 
do not aid in much lovastatin production when compared to 
NH4Cl, MgSO4 and NaCl when present in medium inocu-
lated with M purpureus 369 [27]. Various physico-
nutritional parameters that govern lovastatin production have 
been well documented [5]. 
 Presence of one amino acid is mandatory in the growth 
media. Riboflavin, Pyridoxine and Calcium phosphate when 
used as supplements invariably increased yield, except for 
thiamine. Methionine is suited as it is directly involved in 
biosynthetic pathway and gives a yield of180 μg/ml [5]. It is 
necessary to maintain a striking balance between carbon and 
nitrogen source for obtaining desirable lovastatin production 
as they regulate the biomass and metabolite production [21]. 
 Incorporation of various supplements to the growth me-
dium has been studied. Tween-80 addition increases the 
yield whereas ZnSO4 had no effect on yield, but MgSO4 de-
creased yield by 4.11% [28]. Addition of acetic acid at range 
of 0.1% -0.3% also favoured good yield. Glycerol (3%), 
NaNO3 (0.2%) contributed in higher yield. A glycerol level 
above 0.3% decreased titre as it affected fungal cell perme-
ability [26]. Butyrolactone and Dodecane (2.5%) increased 
the yield by 3-4 fold [5]. Sodium acetate supplementation 
triggers better yield by acting as a precursor for statin syn-
thesis [21]. 
 The use of agro-based wastes (wheat bran, corn hull and 
rice husk), fruit wastes (sugarcane bagasse, orange peel and 
orange pulp) and their combination has been studied [18, 19, 
24]. Addition of nutrient medium to dried substrate has also 
been the subject of study with contradictory results. Lower 
yield of lovastatin is noted when glucose, lactose, sucrose is 
incorporated into solid substrate [24]. Glucose, lactose and 
sucrose decreased the yield of lovastatin to 2101±51, 
2534±29 and 2435±38 ?g g-1 Dried Fermented Matter) re-
spectively, contradictorily a higher yield was recorded when 
sweet sorghum syrup is incorporated with nutrient solution 
[22].  
 Mutation by Ethyl Methyl Sulphonate (EMS) and UV of 
Aspergillus terreus KLV28mu21 recorded higher yield [18]. 
Aspergillus terreus isolated from contaminated oyster mush-
Table 2. Lovastatin Production by SSF 
S. No. Substrate Microorganism Lovastatin Yield References 
1 Black gram husk Aspergillus fischeri 12.63 mg/g Chanakya et al., 2011 [23] 
2 
Black gram husk 
Green gram husk 
Orange peel 
Wheat bran 
P funiculosum NCIM 1174 
4.8 mg/g 
4.6 mg/g 
3.4 mg/g 
5.3 mg/g 
Reddy et al., 2011 [19] 
3 Wheat bran Aspergillus terreus 983.3 ?g/g  Jaivel and Marimuthu, 2010 [22] 
4 Rice based medium Monascus purpureus 3.42 mg/g Panda et al., 2009 [27] 
5 Wheat bran Aspergillus terreus KLVB28mu21 1110g/gm Prabhakar et al., 2011 [18] 
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room bed [22] subjected to EMS and UV mutation (strains 
JPM-EMS2and JPM-UV2) produced lovastatin in apprecia-
ble quantity (948.50mg/L and 1553.02 mg/L) [29].  
 The higher lovastatin production in SSF is primarily re-
lated to enhanced transcriptional rates of biosynthetic genes 
lov E and lov F resulting in yield increase by 4.6 fold and 2 
fold respectively. Genetically engineered A terreus could 
synthesise 2,2 dimethyl butyrate (side chain of simvastatin) 
and produce simvastin directly rather than lovastatin [6]. By 
isolating DNA, RNA and analysing them by corresponding 
blotting techniques it was confirmed that during SSF the 
gene transcript levels of lov genes (lov b and lov f) was 
higher when compared to Smf. The expression of gldB 
(NADP dependent glycerol dehydrogenase), gene for osmo-
tolerance, in SSF indicated the role of osmotic genes in A 
nidulans when inert substrate poly-urethane foam is used 
[30]. 
 Response Surface Methodology (RSM) approach has 
been well adopted to assess lovastatin yield and determine 
the optimum fermentation parameters. A temperature of 
29.46OC, fermentation time of 14.43 days with an initial in-
oculum level of 5 ml at pH 6.00 yields 3.432 mg/g [31] of 
lovastatin using M purpureus MTCC 369 under SSF. Fer-
mentation studies have been revealed the temperature range 
of 28OC -30OC as the best suited and at pH range between 5-
6 and for Aspergillus fischerii relative humidity of 60%, pH 
5, temperature 300C with lactose and malt extract as the op-
timum is best suited [23]. 
 SSF hold true potential for production of many industri-
ally important products. The limitations that may be encoun-
tered in SSF are in controlling of process parameters and 
scale up from laboratory to industrial level [38]. 
CONCLUSION 
 Lovastatin production has gained large scale importance 
with more emphasis on use of SSF approach. This has re-
sulted in continual search for novel and cheaper substrates 
with stress on optimisation of production technology. The 
molecular level studies also substantiate the role of using 
SSF technology. With the pleiotropic effects unfolding, stat-
ins may be a master key to control or regulate many major 
diseases in the future.  
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